Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults β₯65 Years of Age
PHASE2
The present study is designed to confirm the safety and immunogenicity of t...
Status
Completed
Location
Antwerp University Centre for the Evaluation of Vaccination
Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above
PHASE1
In this study, the safety and immunogenicity of the current formulation of ...
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
PHASE3
The present study, randomized, single-blind, dose-ranging, multicenter stud...